ப்ரெட் கிரீன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ரெட் கிரீன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ரெட் கிரீன் Today - Breaking & Trending Today

Tech Moves: Adaptive Biotech co-founders join life sciences SPAC; new edtech execs; and more


Tech Moves: Adaptive Biotech co-founders join life sciences SPAC; new edtech execs; and more
April 15, 2021 at 4:44 pm
Underwritten by
Tech Moves covers notable hires, promotions and personnel changes in the Pacific NW tech community. Submissions: [email protected]
Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, a theoretical physicist turned computational biologist who is the company’s chief scientific officer. (Adaptive Biotechnologies Photo)
Adaptive Biotechnologies co-founders and brothers Chad and Harlan Robins are among the directors of a new life sciences SPAC.
The blank check company is called CM Life Sciences III Inc. and listed on the NASDAQ starting April 7. The SPAC is targeting companies in “three separate areas of the life sciences industry that are often fragmented life sciences tools, synthetic biology and diagnostics.” ....

New York , United States , Fred Hutchinson Cancer Research Center , Steven Halliwell , Matthew Kennedy , Harlan Robins , Eli Casdin , Brett Greene , Frank Catalano , Santa Barbara , Wesley Yurovchak , Arya Sciences Acquisition Corp , Amazon Web Services , Cm Life Sciences , Chad Robins , Adaptive Biotechnologies , Adaptive Biotechnologies Photo , Seattle Based Adaptive Biotechnologies , Casdin Capital , Seattle Based Nautilus Biotechnology , Renaissance Capital , Khosla Ventures , Life Science Washington , Fred Hutchinson Cancer Research , Promethean Photo , Lance Solomon ,

Cybin Inc. Releases Financial Highlights and Provides Business Update


 Cybin Inc. Releases Financial Highlights and Provides Business Update
Successful bought deal offering brings total capital raised to-date to approximately $90 million Increased patent applications filed to 10, covering novel molecules, delivery systems, deuterated tryptamines and phenethylamines – Adelia Therapeutics acquisition expands scientific team, IP portfolio and diversifies development pipeline Partnership with Kernel provides access to neuroimaging …
Successful bought deal offering brings total capital raised to-date to approximately $90 million
Increased patent applications filed to 10, covering novel molecules, delivery systems, deuterated tryptamines and phenethylamines –
Adelia Therapeutics acquisition expands scientific team, IP portfolio and diversifies development pipeline
Partnership with Kernel provides access to neuroimaging technology, enabling the potential quantification of psychedelic therapeutics – ....

United States , Lisam Wilson , Doug Drysdale , Alex Nivorozhkin , Tim Regan Scott Eckstein , Jukka Karjalainen , Jacqueline Poriadjian , Annie Graf , Brett Greene , Michael Palfreyman , Gabriel Fahel , Cybin Inc , Regulatory Affairs , Drug Administration , Site Communications Inc , Strategic Communications , Adelia Therapeutics Inc , Health Canada , Adelia Therapeutics , Kernel Flow , Chief Executive , Lori Challenger , Chief Research Officer , Chief Science Officer , Chief Innovation Officer , Aaron Bartlone ,

CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings


Adelia”) for up to CDN$20,161,575 (approximately USD$15.75 million) (the “
Transaction”).
Transaction Highlights
Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications. Selective modification, through deuteration of psychedelic parent molecules, allows control of the duration of action of these new chemical entities, enabling the design of both short and long-acting treatments.
Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic regimens, as well as six patent applications.
Adelia contributes an expanding library of psychedelic derivative drug development candidates. The first lead compounds are expected to enter clinical studies in 2021, subject to receipt of approvals. ....

United States , Northeastern University , Brett Greene , Michaelg Palfreyman , Michael Palfreyman , Doug Drysdale , Alex Nivorozhkin , Eli Lilly , Brettj Greene , Development Officer , Cybin Corp , Nova Capital International , Cybin Inc , Drug Administration , Cybin Us Holdings Inc , Health Canada , Chief Executive Officer , Chief Strategy Officer , Drug Discovery , Chief Operating Officer , Chief Scientific , Chief Research , Chief Innovation , Adelia Shareholders , Classb Share , Classb Shares ,